This 5%-yielding ASX 200 dividend giant looks like a hidden gem to me

This is a very healthy opportunity in my opinion.

| More on:
cheap stocks represented by open brief case with golden light shining from it

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sonic Healthcare Ltd (ASX: SHL) is an S&P/ASX 200 Index (ASX: XJO) dividend giant, which looks like a hidden gem in my opinion.

How big is the Sonic Healthcare business? It has a market capitalisation of almost $15 billion, according to the ASX. It's one of the larger businesses on the ASX, though it's not quite as large as a company like Woolworths Group Ltd (ASX: WOW) and Telstra Group Ltd (ASX: TLS).

What does Sonic Healthcare do?

It's best-known as being a global pathology business. In other words, it's an ASX healthcare share that helps healthcare professionals test patients and figure out what's wrong.

Sonic Healthcare has sizeable operations in a number of countries including the US, Australia, Germany, the UK, Switzerland, Belgium and New Zealand.

The business also has a large radiology division which made $796 million of revenue in FY23. In total, this ASX 200 dividend giant made total revenue of $8.17 billion last financial year.

Why it's a dividend leader

The business has been paying a dividend for a number of decades and it increased the dividend most years. Indeed, the company's leadership has a progressive dividend policy. In other words, the board of directors want to grow the dividend for shareholders, if possible.

There are very few businesses on the ASX that have grown their dividend as frequently as Sonic Healthcare over the last two decades.

The ASX 200 dividend giant is not guaranteed to grow its dividend every year, but I think being in the healthcare sector means the business is defensive enough to perform for income-focused shareholders every year.

It's growing profit with organic growth – it's benefiting from the ageing population tailwind as well as growing populations. Sonic Healthcare also has been steadily making acquisitions, increasing its scale in Australia, the US and Europe.

Sonic Healthcare is also investing in AI, which could help the company's operations and margins in the future.

Dividend yield

In FY23, the business paid a dividend per share of $1.04. That translates into a trailing grossed-up dividend yield of 4.7%.

According to Commsec, the business could pay a dividend per share of $1.071. If it did pay that, this would translate into a forward grossed-up dividend yield of close to 5%.

While it's not the biggest yield around, I like the history of reliability and growth that this ASX 200 dividend giant has offered.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »